Stock MCRB SERES THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
0.812 USD +15.70% Intraday chart for Seres Therapeutics, Inc. +12.19% -42.00%
Jun. 24 Omega Therapeutics, Inc. Appoints Richard N. Kender to Board of Directors CI
Jun. 11 Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Omega Therapeutics, Inc. Appoints Richard N. Kender to Board of Directors
Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic
Nestlé Unit to Buy Vowst Assets from Seres Therapeutics
Sector Update: Health Care Stocks Advance Thursday Afternoon
Seres Therapeutics to Sell Vowst Assets to Nestle Health Science
Nestlé : rachat d'un médicament issu du microbiote
Nestlé Health holt sich Mittel zur Behandlung von Darmerkrankungen ins Haus
Seres Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Foreign automakers eager for Chinese partners at Beijing auto show
Battle for 'tech luxury' in China as EVs get smarter - and cheaper
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Seres Therapeutics Appoints Marella Thorell as Executive Vice President
Kenneth Steiner Submits a Shareholder Proposal to Seres Therapeutics
Seres Therapeutics Announces VOWST? Commercial Launch Update and US FDA Fast Track Designation for SER-155
Huawei's new smart car firm valued up to $35 bln amid advanced stake talks -sources
Seres Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Grégory Behar Resigns from Board of Directors of Seres Therapeutics, Inc
Seres Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MCRB Stock
  4. News Seres Therapeutics, Inc.
  5. Other languages